All In MedTech

FDA Clearance Tracker · P970055

BIOTRIN PARVOVIRUS IGM EIA (V619IMUS)

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Aug 6, 1999 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Aug 6, 1999

Approved

Time to decision

708 days

Received Aug 28, 1997. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P970055
Device name
BIOTRIN PARVOVIRUS IGM EIA (V619IMUS)
Applicant
Diasorin
Applicant location
Stillwater, MN
Received
Aug 28, 1997
Decided
Aug 6, 1999
Decision
Approved
Supplements
21 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MYM

FDA's approval statement

As written in FDA's record.

The device is intended for the qualitative detection if IgM antibodies to B19 virus (B19V, previously known as human parvovirus B19) in human seru, lithium heparin, EDTA, and citrated plasma. This test, in conjunction with the Biotrin Parvovirus B19 IgG Enzyme Immunoassay, may be used for testing women of childbearing age to determine their serological status where there is a suspicion of exposure with B19V. The results of these assays may be used to make a serological determination of past, recent, or current infection with B19V. The clinician should consider the results of these assays as presumptive for risk of fetal infection with B19V. The test may also be used for all patients as an aid in the diagnosis of fifth disease (erythema infectiosum).

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code MYM (ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGM).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Diasorin

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.